secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001493152-22-023263
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity reports Q1 FY2023 revenue $2.1M, net loss $5M, launches Biotres and Bioheart
--------------------------------------------------------------------------------

- Revenue $2.1M; gross margin 60% consistent with FY22; net loss $5M ($0.098/sh); adjusted loss $0.085/sh.
- Launched Biotres wireless holter patch after FDA clearance; also launched Biokit and Bioheart.
- Expanded physician network to 29 states with over 2,000 physicians using products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222023263/0001493152-22-023263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222023263/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-023263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer